GuruFocus.com
Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q4 2025 Result
➖
AI Sentiment
Neutral
4/10
- Home
- DAWN
as of 02-24-2026 4:00pm EST
$12.02
+$0.36
+3.09%
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.2B | IPO Year: | 2021 |
| Target Price: | $27.56 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | 56.96 |
| 52 Week Low/High: | $5.63 - $13.20 | Next Earning Date: | 04-13-2026 |
| Revenue: | $131,161,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 18.59% | Revenue Growth (next year): | 49.98% |
| P/E Ratio: | -14.10 | Index: | N/A |
| Free Cash Flow: | -80282000.0 | FCF Growth: | N/A |
AI-Powered DAWN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 64.74%
64.74%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
Dubow Adam
Sell
Gen Counsel & Secretary
DAWN Feb 17, 2026
Avg Cost/Share
$11.60
Shares
6,395
Total Value
$74,187.76
Owned After
72,694
SEC Form 4
Bender Jeremy
Sell
CHIEF EXECUTIVE OFFICER
DAWN Feb 17, 2026
Avg Cost/Share
$11.60
Shares
15,459
Total Value
$179,338.31
Owned After
204,603
SEC Form 4
Merendino Lauren
Sell
Chief Commercial Officer
DAWN Feb 17, 2026
Avg Cost/Share
$11.60
Shares
5,814
Total Value
$67,447.63
Owned After
60,157
SEC Form 4
York Charles N II
Sell
COO and CFO
DAWN Feb 17, 2026
Avg Cost/Share
$11.60
Shares
6,065
Total Value
$70,359.46
Owned After
312,025
SEC Form 4
VASCONCELLES MICHAEL
Sell
Head of Research and Dev.
DAWN Feb 17, 2026
Avg Cost/Share
$11.60
Shares
2,728
Total Value
$31,647.26
Owned After
4,397
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dubow Adam | DAWN | Gen Counsel & Secretary | Feb 17, 2026 | Sell | $11.60 | 6,395 | $74,187.76 | 72,694 | |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | Feb 17, 2026 | Sell | $11.60 | 15,459 | $179,338.31 | 204,603 | |
| Merendino Lauren | DAWN | Chief Commercial Officer | Feb 17, 2026 | Sell | $11.60 | 5,814 | $67,447.63 | 60,157 | |
| York Charles N II | DAWN | COO and CFO | Feb 17, 2026 | Sell | $11.60 | 6,065 | $70,359.46 | 312,025 | |
| VASCONCELLES MICHAEL | DAWN | Head of Research and Dev. | Feb 17, 2026 | Sell | $11.60 | 2,728 | $31,647.26 | 4,397 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
Compare DAWN vs Leading Stocks
See how DAWN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.